+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global High Potency Active Pharmaceutical Ingredient (HPAPI) Market (2022-2027) by Type, Synthesis, Manufacturer, Therapeutic Application, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • PDF Icon

    Report

  • 172 Pages
  • August 2022
  • Region: Global
  • Infogence Global Research
  • ID: 5669419

According to the Germany Trade & Invest (GTAI) article "Covid-19 Fuels Debate over API Production Locations," in April 2020, around 60% of APIs, including high-potency APIs of the world, are manufactured in India or China

The Global High Potency Active Pharmaceutical Ingredient (HPAPI) Market is estimated to be USD 27.94 Bn in 2022 and is expected to reach USD 49.11 Bn by 2027, growing at a CAGR of 11.94%.

Market Dynamics

Market dynamics are forces that impact the prices and behaviors of the Global High Potency Active Pharmaceutical Ingredient (HPAPI) Market stakeholders. These forces create pricing signals which result from the changes in the supply and demand curves for a given product or service. Forces of Market Dynamics may be related to macro-economic and micro-economic factors. There are dynamic market forces other than price, demand, and supply. Human emotions can also drive decisions, influence the market, and create price signals.

As the market dynamics impact the supply and demand curves, decision-makers aim to determine the best way to use various financial tools to stem various strategies for speeding growth and reducing risks.

Market Segmentations

The Global High Potency Active Pharmaceutical Ingredient (HPAPI) Market is segmented based on Type, Synthesis, Manufacturer, Therapeutic Application, and Geography.
  • By Type, the market is classified into Innovative HPAPIS and Generic HPAPIS.
  • By Synthesis, the market is classified into Biotech API and Synthetic API.
  • By Manufacturer, the market is classified into Captive API Manufacturers
Merchant API Manufacturers.
  • By Therapeutic Application, the market is classified into Oncology, Hormonal Imbalance, and Glaucoma.
  • By Geography, the market is classified into Americas, Europe, Middle-East & Africa and Asia-Pacific.

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are AbbVie, Inc., BASF SE, Bayer Ag, Bristol-Myers Squibb Company, Carbogen Amcis Ag, Eli Lilly and Company, F Hoffmann La Roche Ltd., Merck & Co., Inc., Novartis Ag, Pfizer, Inc., Sanofi SA, etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

The report presents a detailed Ansoff matrix analysis for the Global High Potency Active Pharmaceutical Ingredient (HPAPI) Market. Ansoff Matrix, also known as the Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.

The analyst analyses the Global High Potency Active Pharmaceutical Ingredient (HPAPI) Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global High Potency Active Pharmaceutical Ingredient (HPAPI) Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains a competitive analysis using Positioning Quadrants, the analyst's competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including the parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 IGR Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Drivers
4.1.1 Increasing Demand for Oncology Drugs
4.1.2 Ongoing Expansion of Pharmaceutical and CDMO Industries across the Globe
4.1.3 Increasing Focus of Leading Pharmaceutical Companies on HPAPIs
4.2 Restraints
4.2.1 High Costs Associated with the Development of HPAPI
4.3 Opportunities
4.3.1 Favorable Governmental Approvals for New Molecular Entities
4.3.2 Ongoing Research and Development Activities for Novel HPAPI
4.4 Challenges
4.4.1 Concerns Associated with the Cytotoxic Nature of High Potency APIs
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
5.5 PESTLE Analysis
6 Global High Potency Active Pharmaceutical Ingredient (HPAPI) Market, By Type
6.1 Introduction
6.2 Innovative HPAPIS
6.3 Generic HPAPIS
7 Global High Potency Active Pharmaceutical Ingredient (HPAPI) Market, By Synthesis
7.1 Introduction
7.2 Biotech API
7.3 Synthetic API
8 Global High Potency Active Pharmaceutical Ingredient (HPAPI) Market, By Manufacturer
8.1 Introduction
8.2 Captive API Manufacturers
8.3 Merchant API Manufacturers
9 Global High Potency Active Pharmaceutical Ingredient (HPAPI) Market, By Therapeutic Application
9.1 Introduction
9.2 Oncology
9.3 Hormonal Imbalance
9.4 Glaucoma
10 Americas' High Potency Active Pharmaceutical Ingredient (HPAPI) Market
10.1 Introduction
10.2 Argentina
10.3 Brazil
10.4 Canada
10.5 Chile
10.6 Colombia
10.7 Mexico
10.8 Peru
10.9 United States
10.10 Rest of Americas
11 Europe's High Potency Active Pharmaceutical Ingredient (HPAPI) Market
11.1 Introduction
11.2 Austria
11.3 Belgium
11.4 Denmark
11.5 Finland
11.6 France
11.7 Germany
11.8 Italy
11.9 Netherlands
11.10 Norway
11.11 Poland
11.12 Russia
11.13 Spain
11.14 Sweden
11.15 Switzerland
11.16 United Kingdom
11.17 Rest of Europe
12 Middle East and Africa's High Potency Active Pharmaceutical Ingredient (HPAPI) Market
12.1 Introduction
12.2 Egypt
12.3 Israel
12.4 Qatar
12.5 Saudi Arabia
12.6 South Africa
12.7 United Arab Emirates
12.8 Rest of MEA
13 APAC's High Potency Active Pharmaceutical Ingredient (HPAPI) Market
13.1 Introduction
13.2 Australia
13.3 Bangladesh
13.4 China
13.5 India
13.6 Indonesia
13.7 Japan
13.8 Malaysia
13.9 Philippines
13.10 Singapore
13.11 South Korea
13.12 Sri Lanka
13.13 Thailand
13.14 Taiwan
13.15 Rest of Asia-Pacific
14 Competitive Landscape
14.1 IGR Competitive Quadrant
14.2 Market Share Analysis
14.3 Strategic Initiatives
14.3.1 M&A and Investments
14.3.2 Partnerships and Collaborations
14.3.3 Product Developments and Improvements
15 Company Profiles
15.1 AbbVie, Inc.
15.2 API Pharma Tech, LLC
15.3 AstraZeneca PLC
15.4 Asymchem Inc.
15.5 Aurobindo Pharma Ltd.
15.6 BASF SE
15.7 Bayer Ag
15.8 BDR Pharmaceuticals Internationals Pvt. Ltd.
15.9 Bristol-Myers Squibb Company
15.10 C.H. Boehringer Sohn AG & Ko. KG
15.11 Carbogen Amcis Ag
15.12 Eli Lilly and Company
15.13 F Hoffmann La Roche Ltd.
15.14 Lonza Group Ag
15.15 Merck & Co., Inc.
15.16 Novartis Ag
15.17 Pfizer, Inc.
15.18 Sanofi SA
15.19 Teva Pharmaceutical Industries Ltd.
15.20 Viatris, Inc.
16 Appendix
16.1 Questionnaire

Companies Mentioned

  • AbbVie, Inc.
  • API Pharma Tech, LLC
  • AstraZeneca PLC
  • Asymchem Inc.
  • Aurobindo Pharma Ltd.
  • BASF SE
  • Bayer Ag
  • BDR Pharmaceuticals Internationals Pvt. Ltd.
  • Bristol-Myers Squibb Company
  • C.H. Boehringer Sohn AG & Ko. KG
  • Carbogen Amcis Ag
  • Eli Lilly and Company
  • F Hoffmann La Roche Ltd.
  • Lonza Group Ag
  • Merck & Co., Inc.
  • Novartis Ag
  • Pfizer, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris, Inc.